Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Hybrigenics    ALHYG   FR0004153930

HYBRIGENICS (ALHYG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on HYBRIGENICS
2017HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) and..
PU
2017HYBRIGENICS : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 20..
PU
2017HYBRIGENICS : gets European patent protection for inhibitors of Ubiquitin-Specif..
PU
2017HYBRIGENICS : full year 2016 results
PU
2017HYBRIGENICS : Strategic refocusing on biopharmaceutical R&D
PU
2017HYBRIGENICS : Encouraging preliminary results of the Phase II clinical study of ..
PU
2017HYBRIGENICS' : patent estate of inhibitors of ubiquitin specific proteases conti..
PU
2016HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the United..
PU
2016HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase I..
PU
2014HYBRIGENICS : 2014 first-half results and highlights
PU
2014HYBRIGENICS : successfully raised € 4.6 million
PU
2014HYBRIGENICS : invests in its genomic capabilities
PU
2014HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is ex..
PU
2014HYBRIGENICS : revenus et trésorerie au premier semestre 2014
PU
2013HYBRIGENICS : Hybrigenics' General Meeting highlights - Focus on inecalcitol rec..
PU
2013HYBRIGENICS : Update on the clinical study of inecalcitol in chronic lymphocytic..
PU
2013HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging..
PU
2013HYBRIGENICS : Hybrigenics' Technology Platform Successfully Applied to the Study..
BU
2013HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in c..
PU
2013HYBRIGENICS : launches a new service to screen interactions between small molecu..
PU
2012HYBRIGENICS : green ligt for two European patents protecting new oral formulatio..
PU
2012HYBRIGENICS : launches a new website
PU
2012HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same..
PU
2012HYBRIGENICS : Hybrigenics' General Meeting Highlights
PU
2012HYBRIGENICS : Bryan, Garnier & Co initiates coverage of Hybrigenics with a targe..
BU
2012HYBRIGENICS : Bryan Garnier initiates coverage of Hybrigenics with a target pric..
PU
2012HYBRIGENICS : completed its private placement to institutional investors up to E..
PU
2012HYBRIGENICS : gets approval and financing for a phase II clinical trial of oral ..
PU
Financials (€)
Sales 2017 1,25 M
EBIT 2017 -7,59 M
Net income 2017 -7,52 M
Finance 2017 7,50 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 14,5x
EV / Sales 2018 8,81x
Capitalization 25,6 M
Chart HYBRIGENICS
Duration : Period :
Hybrigenics Technical Analysis Chart | ALHYG | FR0004153930 | 4-Traders
Technical analysis trends HYBRIGENICS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,11 €
Spread / Average Target 102%
EPS Revisions
Managers
NameTitle
Rémi Delansorne Chief Executive Officer & Director
Guillaume Floch Chief Financial Officer
Jean-François Dufour-Lamartinie Head-Clinical Research & Development
Piet Serrure Independent Director
Albert Saporta Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HYBRIGENICS-11.61%31
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873